The total return over the past 12 months is -35.41% vs. +15.54% for the S&P 500. So far it's up +34.82% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (35.41%) | (27.31%) | (38.17%) | (3.34%) | N/A | N/A |
| Total Return CAGR | (35.41%) | (27.31%) | (38.17%) | (3.34%) | N/A | N/A |
| Revenue CAGR | +12.58% | +3.91% | +7.31% | +20.32% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Intellia Therapeutics, Inc. (NTLA)
| Year | Start price | End price | NTLA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $8.99 | $12.12 | +34.82% | +12.91% | +21.91% |
| 2025 | $11.66 | $8.99 | (22.90%) | +17.72% | (40.62%) |
| 2024 | $30.49 | $11.66 | (61.76%) | +24.89% | (86.65%) |
| 2023 | $34.89 | $30.49 | (12.61%) | +26.19% | (38.80%) |
| 2022 | $118.24 | $34.89 | (70.49%) | (18.17%) | (52.32%) |
| 2021 | $54.40 | $118.24 | +117.35% | +28.74% | +88.61% |
| 2020 | $14.67 | $54.40 | +270.82% | +18.37% | +252.45% |
| 2019 | $13.65 | $14.67 | +7.47% | +31.22% | (23.75%) |
| 2018 | $19.22 | $13.65 | (28.98%) | (4.56%) | (24.42%) |
| 2017 | $13.11 | $19.22 | +46.61% | +21.70% | +24.91% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
